The mRNA-1273 SARS-CoV-2 vaccine had high short-term efficacy, but its medium-term efficacy and safety are not known. https://nej.md/2YfXzla | The New England Journal of Medicine

Preliminary data indicated high efficacy of an mRNA-based vaccine developed in collaboration between Moderna and the NIAID. The vaccine has now been evaluated in an ongoing phase 3 randomized, controlled trial. New research findings are summarized in a short video. https://nej.md/3tstdX9 | The New England Journal of Medicine

‘Supercharged’ cells are helping scientists at UNSW Medicine & Health's Kirby Institute analyse SARS-CoV-2 variants faster than anywhere else in the world. This will help to identify new variants, test their ability to evade vaccines, and inform the public health response in real time. #COVID19 Read more: unsw.to/supercharged-cells | UNSW

What are the SARS-CoV-2 variants circulating at this time? How are variants classified as variants of interest or concern? What does this mean for the public? WHO’s COVID-19 Technical Lead Dr Maria Van Kerkhove explains in this Science in 5 video. | World Health Organization Western Pacific Region